The Novel Methylation Biomarker NPY5R Sensitizes Breast Cancer Cells to Chemotherapy.

ABSTRACT: Breast cancer (BC) is the most common tumor in women, and the molecular mechanism underlying its pathogenesis remains unclear. In this study, we aimed to investigate gene modules related to the phenotypes of BC, and identify representative candidate biomarkers for clinical prognosis of BC patients. Using weighted gene co-expression network analysis, we here identified NPY5R as a hub gene in BC. We further found that NPY5R was frequently downregulated in BC tissues compared with adjacent tumor-matched control tissues, due to its aberrant promoter CpG methylation which was confirmed by methylation analysis and treatment with demethylation agent. Higher expression of NPY5R was closely associated with better prognosis for BC patients. Gene set enrichment analysis showed that transcriptome sign

SUBMITTER: Liu J 

PROVIDER: S-EPMC8787223 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature